In the race for a first-to-market therapy for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, there have been multiple hopeful contenders; however, none have yet crossed the FDA ...

Studies have shown that obstructive sleep apnea and low nighttime oxygen, which result in oxidative stress, are associated with the progression of non-alcoholic fatty liver disease (NAFLD) in adults.

Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a ...

At the moment, there is a lack of clinically relevant preclinical models for fatty liver disease. This problem has led to most drug candidates that were successful in preclinical development failing ...

∙ Presentation of results during the annual congress of the International Diabetes Federation in Abu Dhabi on December 5, 2017. LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: VALBIOTIS ...

Nonalcoholic fatty liver disease (NAFLD) is very common; as many as 25 percent of adults around the world are impacted by the disorder. In NAFLD, liver cells die, damaging the organ. NALFD can also ...

Please provide your email address to receive an email when new articles are posted on . Irregular meal patterns increased the risk for NAFLD and related metabolic conditions. Time-restricted eating ...

LA JOLLA, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange ...

People at high risk for nonalcoholic fatty liver disease (NAFLD), such as those with type 2 diabetes or medically complicated obesity, should be screened for advanced fibrosis, says new guidance from ...

Grade 3 fatty liver disease is the most severe form of nonalcoholic fatty liver disease (NAFLD). It is associated with a large accumulation of fat in the liver. NAFLD occurs when excessive fat builds ...